Venture(US:VEMLY) Sou Hu Cai Jing·2025-07-23 02:16Group 1 - The core viewpoint is that the innovative pharmaceutical sector in China is expected to maintain its growth momentum, driven by "innovation + internationalization" trends, policy support, and enhanced global competitiveness [1] - The current phase of China's innovative drug industry is identified as the 3.0 era, transitioning from "follower" to "leader," with 2025 projected to be a pivotal year for the emergence of overseas blockbuster drugs, with many products expected to exceed $3-5 billion in peak sales [1] - The medical device industry is also anticipated to improve by 2025, undergoing a similar industrial and policy cycle as the pharmaceutical sector, with accelerated innovation and internationalization [1] Group 2 - The daily trading of the Guotai Healthcare ETF (159377) can fluctuate by up to 20%, tracking the innovative pharmaceutical index (399275), which selects listed companies in the biopharmaceutical and medical device sectors from the ChiNext market [1] - The index focuses on companies with outstanding innovation capabilities and significant growth potential, reflecting the overall performance of related listed companies in the healthcare sector [1]